Go offline with the Player FM app!
REVEALing APOE Results: Making Genetic Disclosures in Alzheimer’s Research
Manage episode 425894401 series 2925702
On this episode of Dementia Matters, Dr. Scott Roberts talks about disclosing genetic test results for APOE, a gene that can increase one’s likelihood of developing Alzheimer’s disease. While this information can be concerning, Dr. Roberts shares that it can empower individuals to take the necessary precautions to lower their risk of developing the disease. He discusses the Risk Evaluation and Education for Alzheimer’s Disease (REVEAL) study, walks us through the APOE disclosure process and shares how it is evolving with the development of new Alzheimer’s treatments.
Guest: Scott Roberts, PhD, interim chair, professor of health behavior & health education, University of Michigan School of Public Health
Show Notes
Read Dr. Roberts’ article, “Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study,” on the SageJournals website.
Decide if you’re a fit forAPOE testing using Virginia Tech’s ‘Gene Test or Not?’ decision aid tool, mentioned at 17:00 in the episode.
Learn more about Dr. Roberts on his University of Michigan profile.
Learn more about APOE by listening to our episode, “DNA Is Not Your Destiny: Genetics and Alzheimer’s Disease Risk,” with Dr. Corinne Engelman on our website.
Read “WRAP data used in study finding a distinct, genetic form of Alzheimer’s disease” on the Wisconsin Alzheimer’s Institute (WAI) website.
Connect with us
Find transcripts and more at our website.
Email Dementia Matters: dementiamatters@medicine.wisc.edu
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production.
100 episodes
Manage episode 425894401 series 2925702
On this episode of Dementia Matters, Dr. Scott Roberts talks about disclosing genetic test results for APOE, a gene that can increase one’s likelihood of developing Alzheimer’s disease. While this information can be concerning, Dr. Roberts shares that it can empower individuals to take the necessary precautions to lower their risk of developing the disease. He discusses the Risk Evaluation and Education for Alzheimer’s Disease (REVEAL) study, walks us through the APOE disclosure process and shares how it is evolving with the development of new Alzheimer’s treatments.
Guest: Scott Roberts, PhD, interim chair, professor of health behavior & health education, University of Michigan School of Public Health
Show Notes
Read Dr. Roberts’ article, “Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study,” on the SageJournals website.
Decide if you’re a fit forAPOE testing using Virginia Tech’s ‘Gene Test or Not?’ decision aid tool, mentioned at 17:00 in the episode.
Learn more about Dr. Roberts on his University of Michigan profile.
Learn more about APOE by listening to our episode, “DNA Is Not Your Destiny: Genetics and Alzheimer’s Disease Risk,” with Dr. Corinne Engelman on our website.
Read “WRAP data used in study finding a distinct, genetic form of Alzheimer’s disease” on the Wisconsin Alzheimer’s Institute (WAI) website.
Connect with us
Find transcripts and more at our website.
Email Dementia Matters: dementiamatters@medicine.wisc.edu
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production.
100 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.